Danting Cao1,2, Andrew M Mikosz2, Alexandra J Ringsby3, Kelsey C Anderson4, Erica L Beatman2, Kengo Koike2,5, Irina Petrache1,2. 1. From the Department of Pharmacology Graduate Training Program, University of Colorado Anschutz Medical Campus, Aurora (D.C., I.P.). 2. Division of Pulmonary, Critical Care and Sleep Medicine (D.C., A.M.M., E.L.B., K.K., I.P.), National Jewish Health, Denver, CO. 3. Department of Chemical and Biomolecular Engineering, University of California Berkeley (A.J.P.). 4. Center for Genes, Environment and Health (K.C.A.), National Jewish Health, Denver, CO. 5. Division of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan (K.K.).
Abstract
OBJECTIVE: MicroRNA-126-3p (miR-126) is required for angiogenesis during organismal development or the repair of injured arterial vasculature. The role of miR-126 in lung microvascular endothelial cells, which are essential for gas exchange and for lung injury repair and regeneration, remains poorly understood. Considering the significant heterogeneity of endothelial cells from different vascular beds, we aimed to determine the role of miR-126 in regulating lung microvascular endothelial cell function and to elucidate its downstream signaling pathways. Approach and Results: Overexpression and knockdown of miR-126 in primary human lung microvascular endothelial cells (HLMVEC) were achieved via transfections of miR-126 mimics and antisense inhibitors. Increasing miR-126 levels in HLMVEC reduced cell proliferation, weakened tube formation, and increased cell apoptosis, whereas decreased miR-126 levels stimulated cell proliferation and tube formation. Whole-genome RNA sequencing revealed that miR-126 was associated with an antiangiogenic and proapoptotic transcriptomic profile. Using validation assays and knockdown approaches, we identified that the effect of miR-126 on HLMVEC angiogenesis was mediated by the LAT1 (L-type amino acid transporter 1), via regulation of mTOR (mammalian target of rapamycin) signaling. Furthermore, downregulation of miR-126 in HLMVEC inhibited cell apoptosis and improved endothelial tube formation during exposure to environmental insults such as cigarette smoke. CONCLUSIONS: miR-126 inhibits HLMVEC angiogenic function by targeting the LAT1-mTOR signaling axis, suggesting that miR-126 inhibition may be useful for conditions associated with microvascular loss, whereas miR-126 augmentation may help control unwanted microvascular angiogenesis.
OBJECTIVE:MicroRNA-126-3p (miR-126) is required for angiogenesis during organismal development or the repair of injured arterial vasculature. The role of miR-126 in lung microvascular endothelial cells, which are essential for gas exchange and for lung injury repair and regeneration, remains poorly understood. Considering the significant heterogeneity of endothelial cells from different vascular beds, we aimed to determine the role of miR-126 in regulating lung microvascular endothelial cell function and to elucidate its downstream signaling pathways. Approach and Results: Overexpression and knockdown of miR-126 in primary human lung microvascular endothelial cells (HLMVEC) were achieved via transfections of miR-126 mimics and antisense inhibitors. Increasing miR-126 levels in HLMVEC reduced cell proliferation, weakened tube formation, and increased cell apoptosis, whereas decreased miR-126 levels stimulated cell proliferation and tube formation. Whole-genome RNA sequencing revealed that miR-126 was associated with an antiangiogenic and proapoptotic transcriptomic profile. Using validation assays and knockdown approaches, we identified that the effect of miR-126 on HLMVEC angiogenesis was mediated by the LAT1 (L-type amino acid transporter 1), via regulation of mTOR (mammalian target of rapamycin) signaling. Furthermore, downregulation of miR-126 in HLMVEC inhibited cell apoptosis and improved endothelial tube formation during exposure to environmental insults such as cigarette smoke. CONCLUSIONS:miR-126 inhibits HLMVEC angiogenic function by targeting the LAT1-mTOR signaling axis, suggesting that miR-126 inhibition may be useful for conditions associated with microvascular loss, whereas miR-126 augmentation may help control unwanted microvascular angiogenesis.
Authors: Kelly S Schweitzer; Brian H Johnstone; Jana Garrison; Natalia I Rush; Scott Cooper; Dmitry O Traktuev; Dongni Feng; Jeremy J Adamowicz; Mary Van Demark; Amanda J Fisher; Krzysztof Kamocki; Mary Beth Brown; Robert G Presson; Hal E Broxmeyer; Keith L March; Irina Petrache Journal: Am J Respir Crit Care Med Date: 2010-08-13 Impact factor: 21.405
Authors: Andreas Schober; Maliheh Nazari-Jahantigh; Yuanyuan Wei; Kiril Bidzhekov; Felix Gremse; Jochen Grommes; Remco T A Megens; Kathrin Heyll; Heidi Noels; Michael Hristov; Shusheng Wang; Fabian Kiessling; Eric N Olson; Christian Weber Journal: Nat Med Date: 2014-03-02 Impact factor: 53.440
Authors: Rald Victor Maria Groven; Carlos Julio Peniche Silva; Elizabeth Rosado Balmayor; Bart Nicolaas Jacobus van der Horst; Martijn Poeze; Taco Johan Blokhuis; Martijn van Griensven Journal: J Orthop Translat Date: 2022-08-31 Impact factor: 4.889